Trial Profile
A phase Ib trial investigating AB-M101 in patients with recurrent Clostridium difficile infections
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs ABM 101 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- 23 Dec 2015 New trial record
- 16 Dec 2015 According to an Assembly Biosciences media release, this trial is expected to start in the second half of 2016.